Nature Communications (Aug 2022)
Limited impact of fingolimod treatment during the initial weeks of ART in SIV-infected rhesus macaques
- Maria Pino,
- Amélie Pagliuzza,
- M. Betina Pampena,
- Claire Deleage,
- Elise G. Viox,
- Kevin Nguyen,
- Inbo Shim,
- Adam Zhang,
- Justin L. Harper,
- Sadia Samer,
- Colin T. King,
- Barbara Cervasi,
- Kiran P. Gill,
- Stephanie Ehnert,
- Sherrie M. Jean,
- Michael L. Freeman,
- Jeffrey D. Lifson,
- Deanna Kulpa,
- Michael R. Betts,
- Nicolas Chomont,
- Michael M. Lederman,
- Mirko Paiardini
Affiliations
- Maria Pino
- Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
- Amélie Pagliuzza
- Centre de Recherche du CHUM and Department of Microbiology, Infectious Diseases and Immunology, Université de Montréal
- M. Betina Pampena
- Department of Microbiology, Perelman School of Medicine, University of Pennsylvania
- Claire Deleage
- AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc.
- Elise G. Viox
- Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
- Kevin Nguyen
- Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
- Inbo Shim
- Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
- Adam Zhang
- Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
- Justin L. Harper
- Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
- Sadia Samer
- Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
- Colin T. King
- Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
- Barbara Cervasi
- Flow Cytometry Core, Emory Vaccine Center, Emory University
- Kiran P. Gill
- Flow Cytometry Core, Emory Vaccine Center, Emory University
- Stephanie Ehnert
- Division of Animal Resources, Emory National Primate Research Center, Emory University
- Sherrie M. Jean
- Division of Animal Resources, Emory National Primate Research Center, Emory University
- Michael L. Freeman
- Center for AIDS Research, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center
- Jeffrey D. Lifson
- AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc.
- Deanna Kulpa
- Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
- Michael R. Betts
- Department of Microbiology, Perelman School of Medicine, University of Pennsylvania
- Nicolas Chomont
- Centre de Recherche du CHUM and Department of Microbiology, Infectious Diseases and Immunology, Université de Montréal
- Michael M. Lederman
- Center for AIDS Research, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center
- Mirko Paiardini
- Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
- DOI
- https://doi.org/10.1038/s41467-022-32698-y
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
Although antiretroviral therapy (ART) is able to successfully suppress plasma viremia in most people living with HIV, ART withdrawal typically results in viral replication and rebound. Authors investigate the effect, in terms of delay in viral replication, and immune cell dynamics in lymphoid tissue, of fingolimod (FTY720) administration at the time of ART initiation in SIV-infected rhesus macaques.
